News | January 27, 1999

GENZYME GENERAL: Genzyme General announces Fresenius will market Sepra products in four European countries

JAN 26, 1999, M2 Communications- Genzyme General (Nasdaq: GENZ) announced today that it has signed an agreement with Fresenius A.G., under which Fresenius will distribute and market Genzyme's Sepra family of products in Germany, Austria, Switzerland, and Luxembourg. Terms of the agreement were not disclosed.

The Sepra products include Seprafilm(R) II Adhesion Barrier and Sepracoat(R) Coating Solution.

"Our marketing agreement with Fresenius will help our efforts to increase sales of our Sepra products in an important segment of the European market," said Henri A. Termeer, president and chief executive officer of Genzyme Corp. "This type of partnership allows us to maximize the value of our products by utilizing the strengths of other companies. Fresenius has long-standing relationships with hospitals in the countries where it will be selling Sepra products, and a very strong sales force in the general surgery market."

Genzyme has established a similar distribution and marketing collaboration with Kaken Pharmaceutical Co., Ltd., to market Seprafilm(R) Bioresorbable Membrane in Japan. Genzyme sells its Sepra products in all other European Union countries and the United States through its own surgical products sales force.

Sepracoat received European CE Mark approval in March 1996 for use in reducing the incidence of newly formed adhesions following abdominal, pelvic, and thoracic surgery. Seprafilm II, a second-generation product with improved elasticity and ease of use, received CE Mark approval in May 1998 for use in both open and laparoscopic surgical procedures, to reduce the incidence of post-surgical abdominal and pelvic adhesions.

Genzyme is a leader in the development of biomaterials for adhesion prevention and is working to establish Seprafilm as the standard of care in colorectal surgeries. The company is developing a family of Sepra anti-adhesive products for use in other indications, including cardiovascular, sinus, and orthopedic surgery. Genzyme is also applying its Sepra technology to develop innovative new products for drug delivery and hernia repair.

Genzyme General develops and markets therapeutic and surgical products and diagnostic products and services. A division of the biotechnology company Genzyme Corporation, Genzyme General has its own common stock intended to reflect its value and track its economic performance.

Fresenius, with headquarters in Bad Homburg, Germany, is an international health care company offering products and services for dialysis, hospital care, and home care.

(C)1994-99 M2 COMMUNICATIONS LTDCONTACT: Genzyme Corporate
Communications department
Tel: +1 617 252 7570